FDA approves Tauklarify for PET imaging of tau neurofibrillary tangle pathology

The FDA has approved Tauklarify as a radiodiagnostic agent for adults with cognitive impairment being evaluated via PET scan to identify tau neurofibrillary tangle pathology indicating Alzheimer’s disease, according to a press release. “As the field continues to advance, clinicians are seeking a more complete understanding of this disease, with tau PET imaging providing information

Raccontata dahealio.commorningstar.combenzinga.comeconomictimes.indiatimes.com